Body Fluid Cell Counts and Cerebrospinal Fluid

Body-fluid cell counts use common counting principles, but each fluid has its own viscosity, expected cell concentration, stability, and clinical meaning. Cerebrospinal fluid (CSF) requires especially rapid handling because cells can deteriorate soon after collection and the specimen is often limited. A reliable result begins with a suitable specimen, a method validated for that fluid, and a report that preserves important limitations.

Selecting and controlling a cell-count method

Manual hemacytometer counts remain useful for fluids with very low cell concentrations, analyzer flags, or specimen properties outside an automated method’s validated limits. Automated body-fluid modes can improve speed and precision within their verified range. They may lose accuracy near the lower limit or misclassify atypical cells, microorganisms, debris, or crystals. The laboratory establishes which fluids can be analyzed, the reportable range, and the findings that trigger a manual count or morphologic review.^1,2

A clot can trap cells and make both the total count and differential unreliable. The usual response is rejection and recollection. When the specimen is irreplaceable, testing may proceed under the laboratory’s policy, with the limitation stated clearly in the report.

Manual hemacytometer testing under the Clinical Laboratory Improvement Amendments (CLIA) includes duplicate patient and control counts. Two chamber measurements from one well-mixed dilution can satisfy the duplicate patient-count requirement. CLIA does not set one percentage agreement limit for all fluids. Each laboratory defines and verifies its own acceptance rule, repeat procedure, calculation, and reporting limits.^3,4

Specimen-specific preparation

Appearance can guide the first dilution. Clear or slightly hazy fluid may be counted undiluted or at a low dilution, while densely cellular or bloody fluid usually needs a greater dilution. The method must place enough cells in a countable chamber area and remain within the laboratory’s verified range. An RBC-preserving aliquot and an RBC-lysing TNC aliquot may therefore use different dilutions.

Viscosity can make mixing and air-displacement pipetting inaccurate. A positive-displacement pipette or another verified transfer method improves delivery of untreated viscous fluid. Validated hyaluronidase treatment can improve homogenization of synovial fluid, but an untreated aliquot is retained when crystal analysis is requested because pretreatment conditions can affect the examination. Semen fixatives and treatments for incomplete liquefaction are covered with semen analysis later in this subject.^1,2

Manual counting sequence

1. Inspect the specimen. Record its color, clarity, volume, and the presence of a clot or visible particles before mixing or centrifugation.
2. Mix the specimen by the validated method so cells are evenly suspended without unnecessary damage.
3. Choose the chamber, counted area, and dilution that place enough cells in a readable range. Visual appearance can guide the first dilution, but appearance alone cannot define it.
4. Prepare separate aliquots when red blood cells (RBCs) and total nucleated cells (TNCs) need different diluents. An isotonic, nonlysing diluent preserves RBCs. A validated lysing diluent can remove RBC interference from a TNC count. Acidic diluents can precipitate synovial-fluid hyaluronate, so fluid-specific procedures matter.
5. Mix the dilution and load both chamber sides without bubbles, overfilling, or drying. Allow cells to settle for the time specified by the method. Mixing, loading, and settling times are chamber- and specimen-specific.
6. Count the selected squares using one consistent boundary rule. For example, include cells touching the top and left borders and exclude cells touching the bottom and right borders. The opposite convention also works when it is applied consistently.
7. Treat the chamber sides as independent measurements. Apply the laboratory’s agreement limit, investigate an unacceptable difference, and repeat the count when required.
8. Calculate and report the concentration with the units and any applicable specimen or method limitation.

An improved Neubauer chamber has a nominal depth of 0.1 mm. A Fuchs-Rosenthal chamber has a nominal depth of 0.2 mm and a larger 16 mm² ruled area, so it holds more fluid over its ruling and suits low-cellularity fluids such as CSF. A low-cellularity fluid may require all available large squares. A denser specimen may use a smaller validated area. Every change in counted area changes the counted volume and must be included in the calculation.^1,2

The general chamber equation is:

The denominator is the counted volume because 1 cubic millimeter equals 1 microliter. A pooled calculation divides the cells from both chamber sides by their combined counted volume. A method that averages the two side counts divides that average by the volume of one side. Chamber depth, counted squares, and dilution all belong to the specific procedure. The Manual Cell-Counting Calculations page explains chamber geometry, dilution factors, duplicate-count examples, and traumatic-tap estimates.

Preparing a stained differential

Direct smears work for cellular fluids. Paucicellular fluids such as normal CSF usually require concentration. In a common cytocentrifuge assembly, a specimen chamber and absorbent card sit against the slide. Centrifugal force deposits cells in a defined area while the card draws away fluid. Cell concentration guides the volume loaded, and a protein supplement is used only when the validated method calls for it. Rotor design, funnel, relative centrifugal force, acceleration, spin time, and specimen volume affect cell recovery and appearance. The laboratory validates these settings for its instrument and fluid types.^1,2

After a Wright or Wright-Giemsa stain, the entire deposit is scanned at low power for cell clumps, organisms, and abnormal cells. A systematic differential follows at higher magnification. Procedures commonly call for 100 cells and may extend the count to 200 or 300 cells when cellularity permits. The report states the actual number classified whenever the usual target cannot be reached. Percentages based on a very small denominator can be misleading.¹

Cytocentrifugation can cause cell loss, uneven recovery, disrupted cytoplasm, nuclear distortion, and artificial cell clustering. These changes can resemble disease. Blasts, lymphoma cells, metastatic cells, or any unexpected atypical population requires review by qualified personnel and, when indicated, flow cytometry or cytopathology. A negative cytocentrifuge preparation from a low-cellularity specimen cannot exclude malignancy.^1,2

CSF formation and laboratory handling

The choroid plexus is traditionally considered a major source of CSF through active secretion, while brain interstitial fluid entering across the ependymal lining also contributes. CSF circulates through the ventricles and subarachnoid spaces, then returns through arachnoid, lymphatic, and other drainage pathways. Tight junctions in choroid-plexus epithelium form the blood-CSF barrier, while tight junctions in central nervous system capillary endothelium help form the blood-brain barrier. These barriers regulate the movement of proteins, cells, antibodies, and drugs. Inflammation, hemorrhage, tumors, impaired flow, and other neurologic disease can change CSF composition.⁵

Lumbar puncture commonly produces three or four sequentially numbered, sterile, additive-free tubes. Tube allocation varies among laboratories and depends on the requested tests, available volume, and risk of contamination. The receiving laboratory’s collection guide determines which tube goes to chemistry, microbiology, cell counts, cytology, and special studies. Cell counts often use a later tube because blood introduced by the puncture declines across the tube sequence.¹ When volume is limited, the laboratory and clinical team set priorities promptly.

Opening pressure is measured by the clinician under defined collection conditions. Position, age, body habitus, sedation, and technique affect interpretation, so a single interval does not apply to every patient. The laboratory records the value and collection conditions when they are provided.

CSF for cell counts and microbiology should reach the laboratory immediately. CSF submitted for bacterial culture is held at room temperature and is never refrigerated. Selected chemistry, serology, and molecular aliquots may permit refrigeration or freezing under the assay instructions and local procedure. Aliquots are separated before a storage condition or processing step can alter another test. The specimen-collection guidance in Specimen Collection, Transport, and Primary Processing provides the broader microbiology framework.

CSF and other specified body fluids are treated as other potentially infectious materials under the Occupational Safety and Health Administration bloodborne-pathogens standard. Universal Precautions, suitable personal protective equipment, splash control, and closed containers apply throughout handling.⁶

Appearance and blood contamination

Normal CSF is clear and colorless. A clear specimen can still contain an abnormal cell count, infection, hemorrhage, malignant cells, or abnormal chemistry. Appearance supplies an early clue and never replaces cell counts or other testing.

Xanthochromia is discoloration of the cell-free supernatant. Pigments appear over time. Visual inspection is subjective and cannot replace validated spectrophotometric bilirubin measurement when investigating suspected subarachnoid hemorrhage. Interpretation depends on the time from symptom onset to lumbar puncture. A very recent hemorrhage may have a clear supernatant, and a traumatic collection can add blood pigments or serum protein.⁷

A decline in RBCs across sequential tubes supports a traumatic collection, but it cannot rule out intracranial hemorrhage. Traumatic collection and hemorrhage can also occur together. A clot or erythrophagocytosis can add supporting evidence, though neither finding determines the source of blood by itself. The measured TNC result remains the primary laboratory result. An estimated correction for peripheral-blood leukocytes may be added according to policy and should never be used to exclude meningitis. The Manual Cell-Counting Calculations page shows the paired blood-count equation and its limitations.

CSF cell count and differential

CSF cell concentrations and differential patterns vary with age, collection site, method, and clinical setting. Adult lumbar CSF commonly contains no more than a few nucleated cells per microliter, while newborn and young-infant intervals are higher. Ventricular and shunt specimens require source-specific interpretation. Use the performing laboratory’s verified intervals; the ASCP BOC Examination Reference Ranges page provides the separate examination ranges used across this textbook.^8,11

Device-associated ventriculitis or shunt infection may produce little inflammation. A normal cell count, glucose, protein, or Gram stain cannot exclude infection. Culture remains central, and the specimen source must be included in the report.⁸

CSF chemistry and immune studies

CSF chemistry is interpreted with the cell count, specimen appearance, collection site, clinical timing, and paired blood measurements when required. Detailed analytical methods remain with Chemistry and Immunology.^9,10,11

The immunoglobulin G (IgG) index adjusts the CSF-to-serum IgG ratio for the CSF-to-serum albumin ratio:

Concentrations within each ratio must use consistent units. The performing laboratory’s interval determines whether the result is increased. The index and oligoclonal bands support a clinical evaluation; neither result identifies one disease by itself. Carbohydrate Metabolism and Glucose Testing covers glucose measurement, and Diseases of the Immune System provides the broader immune-disease context.

Infection testing and pattern correlation

When meningitis is suspected, CSF testing commonly combines Gram stain, culture, TNC count and differential, protein, glucose with a paired blood glucose, and targeted molecular or antigen testing. Blood cultures are collected promptly when bacterial meningitis is suspected and collection is feasible, without delaying urgent antimicrobial treatment. The World Health Organization recommends interpreting these findings together because no single routine CSF result confirms or excludes bacterial meningitis. Culture permits organism recovery and antimicrobial-susceptibility testing. Polymerase chain reaction (PCR) can rapidly detect the organisms included on its panel, including some infections after antimicrobial exposure, but panel limits, low organism burden, and other assay limitations can produce a negative result in an infected patient.^11,12

These are supportive patterns. Early infection, partial treatment, immune status, hemorrhage, malignancy, surgery, and ventricular devices can change them. Cryptococcal antigen testing is more sensitive than India ink for cryptococcal meningitis, while culture remains important for organism recovery.¹³

Primary amebic meningoencephalitis caused by Naegleria fowleri is a rare emergency associated with water entering the nose. The CSF pattern can resemble bacterial meningitis. Direct microscopy and CDC-supported PCR or other specialized testing require immediate consultation; heat fixation during a routine Gram-stain process can destroy amebae.¹⁴

For suspected neurosyphilis, a reactive CSF Venereal Disease Research Laboratory (VDRL) test in a specimen without blood contamination is highly specific in the appropriate clinical setting, but its sensitivity is limited. CSF VDRL is the only FDA-cleared test recommended to aid in the diagnosis of neurosyphilis. CSF fluorescent treponemal antibody absorption has variable specificity and is an off-label adjunct; a negative result can help exclude neurosyphilis only in the appropriate clinical setting. Evidence for CSF Treponema pallidum particle agglutination remains limited. No CSF result is interpreted alone; neurologic findings, serum serology, CSF cells, and protein remain part of the assessment.¹⁵

Detailed dilution arithmetic and examination ranges remain in the Appendix. Chemistry owns quantitative glucose, protein, albumin, and immunoglobulin methods. Microbiology owns organism recovery and identification. The later semen module covers semen-specific fixatives, liquefaction treatment, and chamber applications. The next body-fluid module applies the shared counting principles to synovial and serous fluids.

References

1. Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025.
2. Alcaide Martín MJ, Altimira Queral L, Sahuquillo Frías L, et al. Automated cell count in body fluids: a review. Adv Lab Med. 2021;2(2):149-177. doi:10.1515/almed-2021-0011.
3. Electronic Code of Federal Regulations. 42 CFR §493.1269: Standard: Hematology. Accessed August 29, 2026. eCFR §493.1269.
4. Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services (CLIA). QSO-25-10-CLIA. Revised June 23, 2025. CMS Appendix C.
5. Xiang J, Hua Y, Xi G, Keep RF. Mechanisms of cerebrospinal fluid and brain interstitial fluid production. Neurobiol Dis. 2023;183:106159. doi:10.1016/j.nbd.2023.106159.
6. Occupational Safety and Health Administration. 29 CFR §1910.1030: Bloodborne pathogens. Accessed August 29, 2026. OSHA bloodborne-pathogens standard.
7. National Institute for Health and Care Excellence. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management. NICE guideline NG228. Published November 23, 2022. Updated December 4, 2025. Accessed August 29, 2026. NICE recommendations.
8. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861.
9. Higgins V, Parker ML, Ahmed B, et al. Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian Society of Clinical Chemists (CSCC). Clin Biochem. 2026;142:111098. doi:10.1016/j.clinbiochem.2026.111098.
10. Mayo Clinic Laboratories. Beta-trace protein, body fluid. Accessed August 29, 2026. Mayo Clinic Laboratories test catalog.
11. World Health Organization. WHO Guidelines on Meningitis Diagnosis, Treatment and Care. World Health Organization; 2025. Accessed August 29, 2026. WHO publication page.
12. US Food and Drug Administration. QIAstat-Dx Meningitis/Encephalitis Panel: 510(k) premarket notification, K242256. Decision issued October 29, 2024. Accessed August 29, 2026. FDA 510(k) record.
13. Chang CC, Harrison TS, Bicanic T, et al. Global guideline for the diagnosis and management of cryptococcosis. Lancet Infect Dis. 2024;24(8):e495-e512. doi:10.1016/S1473-3099(23)00731-4.
14. Centers for Disease Control and Prevention. Clinical and laboratory diagnosis for Naegleria fowleri infection. Updated June 5, 2024. Accessed August 29, 2026. CDC diagnostic guidance.
15. Papp JR, Park IU, Fakile Y, et al. CDC laboratory recommendations for syphilis testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1-32. doi:10.15585/mmwr.rr7301a1.